XML 43 R36.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three and nine months ended September 30, 2025 and 2024 is as follows (in thousands):

		Three Months Ended September 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	30,564			$	—			$	—			$	30,564
Cost of revenues			1,628				—				—				1,628
Gross profit			28,936				—				—				28,936
Operating expenses excluding cost of revenues:
Selling and marketing			15,328				—				—				15,328
Research and development			2,146				217				—				2,363
General and administrative			2,595				1,713				11				4,319
Loss on disposal of assets, net			1				—				—				1
Total operating expenses excluding cost of revenues			20,070				1,930				11				22,011
Income (loss) from operations			8,866				(1,930	)			(11	)			6,925
Other income, net			510				217				—				727
Change in fair value of warrant liability			—				(23	)			—				(23	)
Income tax expense			(1,691	)			(2	)			—				(1,693	)
Net income (loss)		$	7,685			$	(1,738	)		$	(11	)		$	5,936
Supplemental disclosure of stock-based compensation expense:
Cost of revenue		$	38			$	—			$	—			$	38
Selling and marketing			24				—				—				24
General and administrative			277				808				—				1,085
Stock-based compensation total		$	339			$	808			$	—			$	1,147

		Nine Months Ended September 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	79,393			$	—			$	—			$	79,393
Cost of revenues			3,673				—				—				3,673
Gross profit			75,720				—				—				75,720
Operating expenses excluding cost of revenues:
Selling and marketing			41,363				—				—				41,363
Research and development			8,512				371				—				8,883
General and administrative			9,008				5,079				16				14,103
Loss on disposal of assets, net			2				—				—				2
Total operating expenses excluding cost of revenues			58,885				5,450				16				64,351
Income (loss) from operations			16,835				(5,450	)			(16	)			11,369
Other income, net			335				354				—				689
Change in fair value of warrant liability			—				2,444				—				2,444
Income tax expense			(3,254	)			(2	)							(3,256	)
Net income (loss)		$	13,916			$	(2,654	)		$	(16	)		$	11,246
Supplemental disclosure of stock-based compensation expense:
Cost of revenue		$	85			$	—			$	—			$	85
Selling and marketing			53				—				—				53
General and administrative			628				1,794				—				2,422
Stock-based compensation total		$	766			$	1,794			$	—			$	2,560

		Three Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	25,488			$	—			$	—			$	25,488
Cost of revenues			958				—				—				958
Gross profit			24,530				—				—				24,530
Operating expenses excluding cost of revenues:
Selling and marketing			13,699				—				—				13,699
Research and development			2,553				222				—				2,775
General and administrative			2,225				1,593				5				3,823
Loss on disposal of assets, net			—				—				—				—
Total operating expenses excluding cost of revenues			18,477				1,815				5				20,297
Income (loss) from operations			6,053				(1,815	)			(5	)			4,233
Change in fair value of warrant liability			—				(228	)			—				(228	)
Other expense, net			(4	)			(71	)			—				(75	)
Income tax expense			(1,074	)			—				—				(1,074	)
Net income (loss)		$	4,975			$	(2,114	)		$	(5	)		$	2,856
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—				237				—			$	237
Stock-based compensation total		$	—			$	237			$	—			$	237

		Nine Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	77,885			$	—			$	—			$	77,885
Cost of revenues			2,707				—				—				2,707
Gross profit			75,178				—				—				75,178
Operating expenses excluding cost of revenues:
Selling and marketing			40,655				—				—				40,655
Research and development			7,639				673				—				8,312
General and administrative			7,031				3,608				6				10,645
Loss on disposal of assets, net			68				—				—				68
Total operating expenses excluding cost of revenues			55,393				4,281				6				59,680
Income (loss) from operations			19,785				(4,281	)			(6	)			15,498
Change in fair value of warrant liability			—				6,973				—				6,973
Other income (expense), net			111				(136	)			—				(25	)
Income tax expense			(5,117	)			—				—				(5,117	)
Net income (loss)		$	14,779			$	2,556			$	(6	)		$	17,329
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	264			$	—			$	264
Stock-based compensation total		$	—			$	264			$	—			$	264

The table below presents total assets as of September 30, 2025 and December 31, 2024.

		September 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	130,030			$	28,997			$	357			$	159,384

		December 31, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	114,248			$	10,790			$	368			$	125,406

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Nine Months Ended September 30, 2025
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	1,046			$	—			$	—			$	1,046

		Nine Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	2,366			$	14			$	—			$	2,380

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration